Greenwich LifeSciences
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3992 Bluebonnet Dr Bldg 14, Stafford, Te...Phone Number
(832) 819-3232Revenue
<$5 MillionStock Symbol
GLSIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Greenwich LifeSciences
Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.Explore more
Greenwich LifeSciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Greenwich LifeSciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Greenwich LifeSciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Greenwich LifeSciences has new funding data
Click to see if Greenwich LifeSciences had a recent Job posting/layoffs
Earning: See what the market has to say on Greenwich LifeSciences recently announced quarterly report
Check out if Greenwich LifeSciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Greenwich LifeSciences
Check if Greenwich LifeSciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Greenwich LifeSciences launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Greenwich LifeSciences as Masked Content
Find more new buyers
Compare Similar Companies to Greenwich LifeSciences
Compare insights from companies similar to Greenwich LifeSciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Greenwich LifeSciences
<$5M
1-10
Public
-
2006
AT
Anu TammareddiManager, Clinical Safety & Operations Specialist
Company Profile Activity
Activity Insights
Greenwich LifeSciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Greenwich LifeSciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Greenwich LifeSciences.
Greenwich LifeSciences Tech Stack
A closer look at the technologies used by Greenwich LifeSciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Person-Based
Greenwich LifeSciences News & Media
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01.Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Greenwich LifeSciences
Sign Up For FreeTo access detailed company insights
Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.... Read More
